Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993677 | 0.88 | PGR (0.44) | PGRFFAR4TRPA1SCN5ASCN9A | |
| SCHEMBL475727 | 0.86 | PGR (0.43) | PGRFFAR4TRPA1SCN5ASCN9A | |
| SCHEMBL16960182 | 0.81 | NOTUM (0.39) | NOTUMFFAR4RAPGEF3USP30HDAC3 | |
| SCHEMBL16962397 | 0.81 | NOTUM (0.39) | NOTUMFFAR4RAPGEF3USP30HDAC3 | |
| SCHEMBL1921486 | 0.80 | NOTUM (0.47) | NOTUMFFAR4RAPGEF3HDAC3HDAC1 | |
| SCHEMBL23384797 | 0.79 | EPAS1 (0.45) | PGRTRPA1SCN5ASCN9A | |
| SCHEMBL4528935 | 0.78 | AR (0.43) | KCNH2AR | |
| SCHEMBL16950774 | 0.78 | PGR (0.39) | PGRFFAR4TRPA1SCN5ASCN9A | |
| SCHEMBL11685204 | 0.78 | PGR (0.41) | KCNH2PGRFFAR4TRPA1SCN5A | |
| SCHEMBL15821592 | 0.78 | PGR (0.39) | PGRFFAR4TRPA1SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017063966-A1 | SUBSTITUTED 2-(1H-PYRAZOL-1-YL)-BENZOTHIAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-20 | — | — | WO | disclosed |
| US-9550757-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550757-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2542089-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | disclosed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| CN-101238127-A | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS INC (US) | 2008-08-06 | — | — | CN | disclosed |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1910367-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007139856-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, MMP10 | KCNH2 4641/4885NOTUM 1037/4885PGR 3608/4885 |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | KCNH2 4243/4885NOTUM 4789/4885PGR 1941/4885 |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | KCNH2 4492/4885NOTUM 1094/4885PGR 3680/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | KCNH2 4492/4885NOTUM 1094/4885PGR 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.